Barclays’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-300
| Closed | -$41.4K | – | 5312 |
|
|
2025
Q4 | $41.4K | Buy |
+300
| New | +$39.3K | ﹤0.01% | 4766 |
|
|
2024
Q4 | – | Sell |
-100,000
| Closed | -$11.5M | – | 5408 |
|
|
2024
Q3 | $11.5M | Buy |
100,000
+20,300
| +25% | +$2.3M | ﹤0.01% | 1386 |
|
|
2024
Q2 | $8.48M | Buy |
+79,700
| New | +$8M | ﹤0.01% | 1263 |
|
|
2021
Q1 | – | Sell |
-80,700
| Closed | -$7.62M | – | 5046 |
|
|
2020
Q4 | $7.62M | Buy |
80,700
+44,100
| +120% | +$3.85M | ﹤0.01% | 1292 |
|
|
2020
Q3 | $3.18M | Sell |
36,600
-2,800
| -7% | -$243K | ﹤0.01% | 1718 |
|
|
2020
Q2 | $3.44M | Sell |
39,400
-14,900
| -27% | -$1.29M | ﹤0.01% | 1659 |
|
|
2020
Q1 | $4.48M | Sell |
54,300
-52,200
| -49% | -$4.66M | ﹤0.01% | 1562 |
|
|
2019
Q4 | $10.1M | Sell |
106,500
-90,500
| -46% | -$8.12M | 0.01% | 1389 |
|
|
2019
Q3 | $17.1M | Buy |
197,000
+127,600
| +184% | +$11.5M | 0.01% | 973 |
|
|
2019
Q2 | $6.34M | Buy |
69,400
+38,933
| +128% | +$3.3M | ﹤0.01% | 1651 |
|
|
2019
Q1 | $2.63M | Sell |
30,467
-18,079
| -37% | -$1.45M | ﹤0.01% | 2290 |
|
|
2018
Q4 | $3.73M | Buy |
48,546
+26,449
| +120% | +$2.06M | ﹤0.01% | 1830 |
|
|
2018
Q3 | $1.71M | Sell |
22,097
-20,423
| -48% | -$1.51M | ﹤0.01% | 3062 |
|
|
2018
Q2 | $2.88M | Sell |
42,520
-22,543
| -35% | -$1.56M | ﹤0.01% | 2219 |
|
|
2018
Q1 | $4.71M | Buy |
65,063
+3,683
| +6% | +$280K | ﹤0.01% | 1684 |
|
|
2017
Q4 | $4.62M | Buy |
61,380
+25,668
| +72% | +$1.94M | ﹤0.01% | 1723 |
|
|
2017
Q3 | $2.75M | Buy |
35,712
+16,852
| +89% | +$1.27M | ﹤0.01% | 2044 |
|
|
2017
Q2 | $1.41M | Buy |
18,860
+14,173
| +302% | +$1M | ﹤0.01% | 2572 |
|
|
2017
Q1 | $312K | Sell |
4,687
-19,084
| -80% | -$1.27M | ﹤0.01% | 3873 |
|
|
2016
Q4 | $1.55M | Sell |
23,771
-2,120
| -8% | -$138K | ﹤0.01% | 2344 |
|
|
2016
Q3 | $1.83M | Buy |
25,891
+18,749
| +263% | +$1.37M | ﹤0.01% | 2071 |
|
|
2016
Q2 | $528K | Sell |
7,142
-9,040
| -56% | -$625K | ﹤0.01% | 3166 |
|
|
2016
Q1 | $1.04M | Sell |
16,182
-6,919
| -30% | -$471K | ﹤0.01% | 2476 |
|
|
2015
Q4 | $1.78M | Sell |
23,101
-2,679
| -10% | -$213K | ﹤0.01% | 2107 |
|
|
2015
Q3 | $2.1M | Sell |
25,780
-11,606
| -31% | -$1.03M | ﹤0.01% | 2073 |
|
|
2015
Q2 | $3.28M | Sell |
37,386
-20,088
| -35% | -$1.84M | ﹤0.01% | 1824 |
|
|
2015
Q1 | $5.05M | Buy |
57,474
+5,692
| +11% | +$505K | 0.01% | 1554 |
|
|
2014
Q4 | $4.27M | Buy |
51,782
+1,004
| +2% | +$83.2K | ﹤0.01% | 1838 |
|
|
2014
Q3 | $4.28M | Buy |
50,778
+1,674
| +3% | +$135K | ﹤0.01% | 1926 |
|
|
2014
Q2 | $3.96M | Sell |
49,104
-4,576
| -9% | -$360K | ﹤0.01% | 1969 |
|
|
2014
Q1 | $4.09M | Buy |
53,680
+9,710
| +22% | +$708K | ﹤0.01% | 1867 |
|
|
2013
Q4 | $3.15M | Sell |
43,970
-9,821
| -18% | -$683K | ﹤0.01% | 2223 |
|
|
2013
Q3 | $3.66M | Sell |
53,791
-5,915
| -10% | -$391K | ﹤0.01% | 1971 |
|
|
2013
Q2 | $3.78M | Buy |
+59,706
| New | +$3.88M | ﹤0.01% | 1864 |
|
Other funds holding NVS
Barclays's NVS Position: Q1 2026 in Review
Barclays increased its Novartis (NVS) stake by 1,727% in Q1 2026, buying an estimated $1.08M and bringing the position to 7,473 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2675.
Barclays first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.8M in Q3 2020. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Barclays held 7,473 shares of Novartis worth $1.14M as of Q1 2026.
- Barclays bought 7,064 Novartis shares in Q1 2026, an estimated $1.08M.
- Novartis made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2675 holding.
- Barclays first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- Barclays's Novartis position peaked at $10.8M in Q3 2020.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.